Please login to the form below

Not currently logged in
Email:
Password:

Former Sanofi SVP Gilles Brisson to chair Mauna Kea

Takes over from Albert Waxman at US endomicroscopy specialists

Gilles Brisson - Mauna Kea TechnologiesGilles Brisson, former senior VP of Sanofi, has been appointed as the chair of Mauna Kea Technologies.

Brisson takes over from Albert Waxman at the US-based medical device company, which is among the leaders in the global endomicroscopy market.

He held his position at Sanofi from 2004 to 2006, having previously spent five years at Aventis before its takeover by Sanofi.

During his time at Aventis, Brisson served as president and CEO of the company's French business, before being promoted to senior VP Europe – the same position he held at Sanofi.

Previously, he was president of Rhone-Poulenc's French business, as well as senior VP corporate development at the France-based chemical and pharmaceutical company, before its merger with Hoechst to form Aventis.

Most recently, Brisson has held the position of chair at Innate Pharma since 2007 and Ethypharm since 2009.

13th April 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics